Major Massachusetts hospitals decide against using Biogen's Aduhelm, with the help of a former FDA adcomm member
Harvard’s Brigham and Women’s Hospital, Massachusetts General Hospital and other affiliated hospitals with Mass General Brigham, the state’s largest health care provider, have decided to not administer Biogen’s new controversial Alzheimer’s drug Aduhelm, serving up another blow to the drug’s lackluster launch.
Mass General Brigham came to its decision on the local company’s drug after an extensive review of its benefits and risks with the help of experts like Aaron Kesselheim, a Harvard professor and physician who was the third member to resign from the FDA advisory committee after FDA signed off on aducanumab even as the adcomm unanimously called on FDA not to approve it.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 142,700+ biopharma pros reading Endpoints daily — and it's free.